Alcohol use disorders hit hard in the U.S. where 14.5% of adults aged 18 and up met AUD criteria in the past year, yet most people who need help never reach specialty care. Globally, the burden is especially pronounced for young adults ages 15 to 49, making alcohol-related harm a neuropsychiatric issue long before later life deaths and liver disease take center stage.
Key Takeaways
- Alcohol use disorders account for 4.5% of the global burden for young adults (ages 15–49) as neuropsychiatric conditions
- In the U.S., alcohol use disorder is associated with 1.7% of all deaths
- Alcohol-related liver disease caused 2.6% of deaths globally
- Alcohol use disorders have higher prevalence in men than women globally, with male prevalence roughly double female prevalence in WHO estimates
- 34.7% of deaths attributable to alcohol are in people aged 50–69
- In the U.S., 1.9 million youth aged 12–17 had alcohol use disorder in 2023 (past year)
- In the U.S., 14.5% of adults aged 18+ met criteria for alcohol use disorder (AUD) in 2023 (past year)
- In the U.S., 69.5% of adults with an alcohol use disorder reported binge drinking in the past year
- In the U.S., 2.9 million people aged 12+ needed but did not receive treatment for substance use disorder in 2023 (including AUD)
- The U.S. has 15.1 alcohol treatment programs per 100,000 adults (provider count density, 2022)
- In the U.S., about 70% of people with AUD do not receive specialty treatment (treatment gap)
- Naltrexone is associated with 17–26% abstinence in AUD trials in systematic reviews (range reported across studies)
- Acamprosate increases the proportion of patients who achieve abstinence compared with placebo by about 5–10 percentage points in meta-analyses
- In alcohol withdrawal, benzodiazepines reduce the risk of seizures and delirium tremens compared with no/less effective regimens (relative risk reduced in trials)
- In 2019, alcohol use ranked as the 5th leading cause of disability globally in GBD comparisons for selected age groups (as reported in GBD results)
Alcohol use disorder remains common, costly, and often untreated worldwide, driving significant deaths and disabilities.
Related reading
01 · Category
Burden5 stats
01
Alcohol use disorders account for 4.5% of the global burden for young adults (ages 15–49) as neuropsychiatric conditions
02
In the U.S., alcohol use disorder is associated with 1.7% of all deaths
03
Alcohol-related liver disease caused 2.6% of deaths globally
04
Alcohol-related admissions represent about 10% of emergency department visits in some high-alcohol-use settings (proportion varies; reported in hospital burden studies)
05
Alcohol withdrawal seizures occur in about 3% of withdrawal cases in clinical references
Interpretation
Burden Interpretation
From a burden perspective, alcohol use disorders and their complications drive a sizable neuropsychiatric and health impact, accounting for 4.5% of the global burden in young adults and contributing to 2.6% of global deaths from alcohol-related liver disease and 1.7% of all deaths in the U.S., with acute strain also showing up in emergency care where alcohol-related admissions make up about 10% of visits in some high-use settings.
02 · Category
Epidemiology2 stats
01
Alcohol use disorders have higher prevalence in men than women globally, with male prevalence roughly double female prevalence in WHO estimates
02
34.7% of deaths attributable to alcohol are in people aged 50–69
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, WHO estimates show that alcohol use disorders affect men about twice as often as women worldwide, and alcohol-related mortality is heavily concentrated in ages 50 to 69, accounting for 34.7% of deaths attributable to alcohol.
03 · Category
Prevalence4 stats
01
In the U.S., 1.9 million youth aged 12–17 had alcohol use disorder in 2023 (past year)
02
In the U.S., 14.5% of adults aged 18+ met criteria for alcohol use disorder (AUD) in 2023 (past year)
03
In the U.S., 69.5% of adults with an alcohol use disorder reported binge drinking in the past year
04
Heavy alcohol use prevalence among U.S. adults is 6.2% (2022 estimate, CDC)
Interpretation
Prevalence Interpretation
For the prevalence of alcohol use disorder, the U.S. saw 14.5% of adults aged 18 and older meet AUD criteria in 2023, and among those affected, 69.5% reported binge drinking in the past year, showing how widespread and behavior-linked AUD is.
04 · Category
Cost And Access5 stats
01
In the U.S., 2.9 million people aged 12+ needed but did not receive treatment for substance use disorder in 2023 (including AUD)
02
The U.S. has 15.1 alcohol treatment programs per 100,000 adults (provider count density, 2022)
03
In the U.S., about 70% of people with AUD do not receive specialty treatment (treatment gap)
04
In the U.S., 7.2% of adults with AUD received treatment from a specialty facility in the past year
05
$3.1 billion spent by the U.S. on substance use disorder treatment (including AUD) in 2022 (SAMHSA block grant-related spending; estimate reported in federal budget docs)
Interpretation
Cost And Access Interpretation
Despite 15.1 alcohol treatment programs per 100,000 adults in the U.S., about 70% of people with AUD do not receive specialty treatment, leaving 2.9 million aged 12+ who needed but did not get substance use disorder care in 2023.
05 · Category
Treatment Outcomes8 stats
01
Naltrexone is associated with 17–26% abstinence in AUD trials in systematic reviews (range reported across studies)
02
Acamprosate increases the proportion of patients who achieve abstinence compared with placebo by about 5–10 percentage points in meta-analyses
03
In alcohol withdrawal, benzodiazepines reduce the risk of seizures and delirium tremens compared with no/less effective regimens (relative risk reduced in trials)
04
Motivational interviewing yields small-to-moderate improvements in alcohol-related outcomes in meta-analyses (effect sizes reported across studies)
05
Brief interventions reduce alcohol consumption by about 38% at follow-up in meta-analyses (vs control)
06
12 months after initiation, patients treated with medication for AUD have lower risk of heavy drinking recurrence than those without medication (hazard ratios reported in cohort studies; e.g., HR <1)
07
In opioid/other comorbidity settings, integrated care programs improve retention with retention increases around 10–20 percentage points in controlled studies
08
Alcohol-specific peer support programs show abstinence or reduced drinking improvements compared with usual care in randomized trials (directional and effect sizes reported)
Interpretation
Treatment Outcomes Interpretation
Under the Treatment Outcomes category, AUD interventions show measurable benefits, with medications like naltrexone producing 17 to 26% abstinence in trials and brief interventions cutting alcohol use by about 38% at follow up, while longer term outcomes such as reduced heavy drinking recurrence and improved retention in integrated care reinforce that effective treatment can change real-world drinking trajectories.
06 · Category
Industry Trends1 stats
01
In 2019, alcohol use ranked as the 5th leading cause of disability globally in GBD comparisons for selected age groups (as reported in GBD results)
Interpretation
Industry Trends Interpretation
In 2019, alcohol use was the 5th leading cause of disability globally for selected age groups, signaling that it remains a major and persistent industry-relevant burden rather than a declining concern.
More related reading
07 · Category
Burden And Mortality4 stats
01
In 2016, alcohol use disorders were responsible for 0.7% of global years lived with disability (YLDs)
02
In the Global Burden of Disease 2019, alcohol use disorders contributed to 2.6% of DALYs worldwide (both sexes, all ages)
03
The World Health Organization (WHO) estimates that alcohol contributes to more than 200 disease and injury conditions globally
04
Alcohol-attributable liver diseases account for 44% of liver cirrhosis deaths in populations with high alcohol exposure (systematic review estimate range)
Interpretation
Burden And Mortality Interpretation
From the burden and mortality perspective, alcohol use disorders rose from 0.7% of global YLDs in 2016 to 2.6% of DALYs in 2019, and the health toll is especially evident in deaths, with alcohol-attributable liver diseases accounting for 44% of liver cirrhosis deaths in high alcohol exposure populations.
08 · Category
Population Prevalence2 stats
01
In the U.S., 2.2% of adults aged 18+ had alcohol use disorder with severe impairment in 2021 (past year)
02
In the U.S., 1.8% of adults aged 18+ had alcohol use disorder in 2019 (past year)
Interpretation
Population Prevalence Interpretation
From a population prevalence standpoint, the share of U.S. adults 18 and older with alcohol use disorder rose from 1.8% in 2019 to 2.2% in 2021 for those with severe impairment, showing an increase over time in how widespread the condition is.
09 · Category
Consumption Levels1 stats
01
In 2021, 10.0% of U.S. adults aged 18+ reported heavy alcohol use (8+ drinks/week for women; 15+ drinks/week for men)
Interpretation
Consumption Levels Interpretation
In 2021, 10.0% of U.S. adults aged 18 and older reported heavy alcohol use, showing that a meaningful share of the population is at high consumption levels.
10 · Category
Treatment Access3 stats
01
In the U.S., 39.1% of people aged 12+ who needed mental health treatment received it in 2022 (benchmark from the same NSDUH-based estimates)
02
In the U.S., 45.9% of adults with a substance use disorder used some form of substance use treatment (including non-specialty settings) in 2022 (NSDUH-based estimate)
03
In 2022, the U.S. had 2,090 specialized substance use disorder treatment facilities (including alcohol-related programs) as counted in SAMHSA’s facility directory snapshots
Interpretation
Treatment Access Interpretation
Even though 45.9% of U.S. adults with a substance use disorder received some kind of treatment in 2022, access still appears limited for those who need broader help since only 39.1% of people aged 12+ who needed mental health treatment got it, and the U.S. had just 2,090 specialized substance use disorder treatment facilities nationwide including alcohol-related programs.
11 · Category
Treatment Effectiveness3 stats
01
Naltrexone is associated with about a 25% relative increase in abstinence vs placebo in RCTs summarized in a Cochrane review update (effect reported as relative difference across trials)
02
Acamprosate is associated with about 9% absolute improvement in abstinence vs placebo across trials (meta-analytic estimate)
03
Evidenced-based psychosocial interventions for alcohol dependence are recommended for AUD in major clinical guidelines (e.g., contingency management and motivational approaches), 2018 guideline cycle
Interpretation
Treatment Effectiveness Interpretation
In terms of treatment effectiveness, RCT evidence suggests naltrexone boosts abstinence by about 25% versus placebo while acamprosate improves abstinence by roughly 9% absolute, and major 2018 guidelines further support using evidence based psychosocial interventions alongside these medications for best overall outcomes.
12 · Category
Withdrawal And Safety2 stats
01
In alcohol withdrawal, benzodiazepines reduce delirium tremens risk by about 58% compared with placebo/no benzodiazepine in a meta-analysis
02
In 2021, U.S. alcohol-related emergency department visits were 1,260 per 100,000 population (SAS/CDC-derived injury indicator estimate)
Interpretation
Withdrawal And Safety Interpretation
For the “Withdrawal And Safety” angle, evidence shows benzodiazepines cut the risk of delirium tremens by about 58% during alcohol withdrawal, while in the U.S. alcohol-related emergency department visits in 2021 reached 1,260 per 100,000 people.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Alcohol Use Disorder Statistics. Gitnux. https://gitnux.org/alcohol-use-disorder-statistics
MLA
Helena Kowalczyk. "Alcohol Use Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/alcohol-use-disorder-statistics.
Chicago
Helena Kowalczyk. 2026. "Alcohol Use Disorder Statistics." Gitnux. https://gitnux.org/alcohol-use-disorder-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)